ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 353
A Longitudinal Cohort Study of Weekly Teriparatide, Denosmab, and Bisphosphonates for Prevention of Vertebral Fractures in Glucocorticoid-Induced Osteoporosis
9:00AM-11:00AM
Abstract Number: 356
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 354
Association Between Bone and Clinical Parameters in Ankylosing Spondylitis
9:00AM-11:00AM
Abstract Number: 381
Associations Between Vitamin D Insufficiency, Osteoporotic Fractures and Comorbidites
9:00AM-11:00AM
Abstract Number: 350
Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study
9:00AM-11:00AM
Abstract Number: 346
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 358
Bone Microstructure Assessed By Hrpqct in Subjects with Hyperuricemia without Arthritis
9:00AM-11:00AM
Abstract Number: 365
Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
9:00AM-11:00AM
Abstract Number: 373
Compared to Non-Users, Current Glucocorticoids Users Have Less Prevalent Fractures at the Same Bone Mass: Results of a Large Cross-Sectional Study
9:00AM-11:00AM
Abstract Number: 349
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 366
Cost-Effective Osteoporosis Treatment Intervention Thresholds Based on FRAX in Portugal
9:00AM-11:00AM
Abstract Number: 384
Dental Treatments, Tooth Extraction, and Osteonecrosis at Jaw in Japanese Patients with Rheumatoid Arthritis; Results from the IORRA Cohort Study
9:00AM-11:00AM
Abstract Number: 363
Determination of the Osteoporotic Vertebral Fractures By a New Quantitative Approach: Intervertebral Volume Index
9:00AM-11:00AM
Abstract Number: 359
Diminished Health-Related Quality of Life As Measured By the Short Form-10 in Children with Hypophosphatasia
9:00AM-11:00AM
Abstract Number: 343
Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
9:00AM-11:00AM
Abstract Number: 377
Hand Bone Impairment By High-Resolution Peripheral Quantitative Computed Tomography in Patients with Diffuse Systemic Sclerosis: Correlation with Clinical Parameters, Quality of Life and Capillaroscopic Findings
9:00AM-11:00AM
Abstract Number: 374
High Prevalence of Osteoporosis and Fractures Is Associated with Abdominal Adiposity and Decreased Muscular Strength in Primary Necrotizing Vasculitides
9:00AM-11:00AM
Abstract Number: 357
Human Parathyroid Hormone for Preventing and Treating Glucocorticoid-Induced Osteoporosis: Cochrane Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 370
Impact of Didactic Lecture on Osteoporosis Screening and Fracture Risk Assessment Among House Staff
9:00AM-11:00AM
Abstract Number: 369
Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity
9:00AM-11:00AM
Abstract Number: 348
Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates
9:00AM-11:00AM
Abstract Number: 352
Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 360
Massive Elimination of Multinucleated Osteoclasts By Eupatilin Is Due to Dual Inhibition of Transcription and Cytoskeletal Rearrangement
9:00AM-11:00AM
Abstract Number: 371
New Vertebral Fractures after Vertebroplasty: Two Year Results from a Randomised Placebo-Controlled Trial
9:00AM-11:00AM
Abstract Number: 380
Osteoporosis Screening and Treatment of Rheumatoid Arthritis Patients at a Teaching Institution
9:00AM-11:00AM
Abstract Number: 378
Osteoporotic Fragility Tibia/Fibula Fractures Are Not Asociated with a Low Body Mass Index: An Observational Study
9:00AM-11:00AM
Abstract Number: 372
Prevalence of Atypical Fractures in a Tertiary Hospital
9:00AM-11:00AM
Abstract Number: 367
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
9:00AM-11:00AM
Abstract Number: 375
RA May Not Confer Addition Risk of Osteoporosis in Male Patients – Results of Cohort Analysis and Literature Review
9:00AM-11:00AM
Abstract Number: 362
Reference Curves of Bone Parameters Obtained By High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) in Healthy Women from 20 to 85 Years Old
9:00AM-11:00AM
Abstract Number: 345
Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
9:00AM-11:00AM
Abstract Number: 344
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
9:00AM-11:00AM
Abstract Number: 347
Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
9:00AM-11:00AM
Abstract Number: 361
Sodium Intake and Osteoporosis. Findings from the Women’s Health Initiative
9:00AM-11:00AM
Abstract Number: 383
Stiffness Index Study in Ehler Danlos Syndrome
9:00AM-11:00AM
Abstract Number: 355
The Clinical and Genetic Spectrum of Low Alkaline Phosphatase in Adults
9:00AM-11:00AM
Abstract Number: 368
The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
9:00AM-11:00AM
Abstract Number: 376
The Relationships Between Bone Mineral Density and Radiographic Features of Hand or Knee Osteoarthritis in Older Adults: Data from the Dong-Gu Study
9:00AM-11:00AM
Abstract Number: 351
Trabecular Bone Score Is Severely Affected in Male Patients with Chronic Obstructive Pulmonary Disease
9:00AM-11:00AM
Abstract Number: 382
Twelve Months after Osteoporosis Associated Fracture – Has Adequate Therapy Been Initiated?
9:00AM-11:00AM
Abstract Number: 379
Validation of a Short Calcium Intake List to Estimate Daily Dietary Calcium Intake of Patients with Osteoporosis
9:00AM-11:00AM
Abstract Number: 364
Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology